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Background: The 6-minute walk test (6MWT) is used to measure exercise capacity and assess prognosis in interstitial
lung disease (ILD). Although the 6MWT is usually considered to be a test of submaximal exercise capacity in ILD, the
physiological load imposed by this test is not well described and 6MWT outcomes are poorly understood. This study
aimed to compare cardiorespiratory responses to 6MWT and cardiopulmonary exercise test (CPET) in people with ILD.
Methods: 47 participants with ILD (27 idiopathic pulmonary fibrosis (IPF), mean age 71 (SD 12) years, diffusing capacity
for carbon monoxide (TLCO) 49(15) %predicted) undertook CPET and 6MWT on the same day in random order.
Oxygen uptake (VO2), ventilation (VE) and carbon dioxide production (VCO2) were assessed during each test using a
portable metabolic cart.
Results: The VO2peak during the 6MWT was lower than during CPET (1.17(0.27) vs 1.30(0.37) L.min
−1, p = 0.001),
representing an average of 94% (range 62-135%) of CPET VO2peak. Achieving a higher percentage of CPET VO2peak on
6MWT was associated with lower TLCO %predicted (r = −0.43, p = 0.003) and more desaturation during walking (r = −0.46,
p = 0.01). The VEpeak and VCO2peak were significantly lower during 6MWT than CPET (p < 0.05). However, participants
desaturated more during the 6MWT (86(6)% vs 89(4)%, p < 0.001). The degree of desaturation was not affected by the
percent of peak VO2 achieved during the 6MWT. Responses were similar in the subgroup with IPF.
Conclusions: On average, the 6MWT elicits a high but submaximal oxygen uptake in people with ILD. However
the physiological load varies between individuals, with higher peak VO2 in those with more severe disease that
may match or exceed that achieved on CPET. The 6MWT is not always a test of submaximal exercise capacity in
people with ILD.
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Exercise limitation is a cardinal feature of interstitial
lung disease (ILD), resulting in reduced ability to under-
take daily activities and poor quality of life [1]. Reduced
peak oxygen uptake (VO2peak) [2-4] and exercise-induced
hypoxemia [2,5] during the cardiopulmonary exercise test
(CPET) are sensitive markers of mortality. Results from
the CPET can also inform exercise prescription in people* Correspondence: a.holland@alfred.org.au
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unless otherwise stated.with ILD undergoing pulmonary rehabilitation. However,
the CPET is not currently recommended as part of rou-
tine monitoring [6] and may not be available in all centres.
The six-minute walk test (6MWT) is a practical and
inexpensive test of exercise tolerance that is commonly
used to stage disease and evaluate treatment responses
in people with ILD [2,7]. A reduced 6-minute walk dis-
tance (6MWD) is a predictor of mortality for people
with idiopathic pulmonary fibrosis (IPF) in some [8,9]
but not all [10] studies. Although the 6MWD has a sig-
nificant relationship with other measures of outcome
such as forced vital capacity (FVC) and diffusing cap-
acity for carbon monoxide (TLCO) across a range ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[2,7,11,12] Some investigators have been reluctant to
recommend the use of the 6MWT as it is unclear what
it actually measures in people with ILD [13]. Whilst it is
often considered a submaximal test, perhaps partially
reflecting functional exercise tolerance [13], one previ-
ous study has suggested that the VO2peak achieved dur-
ing a 6MWT may be equivalent to that during CPET in
people with ILD [14], although this study may not have
been sufficiently powered to detect differences between
the tests.
It is possible that the 6MWT provides unique infor-
mation that is not available from CPET. Oxyhemoglobin
desaturation, a marked feature of the 6MWT in ILD, is a
more consistent predictor of reduced survival than dis-
tance walked [2,15,16]. Data from people with other re-
spiratory diseases have shown greater desaturation
during walking compared to cycling [17], suggesting that
the full extent of exercise-induced desaturation may only
be visible during a walking test. However, an adequately
powered comparison of the cardiorespiratory responses
to CPET and 6MWT in ILD has not been undertaken.
The aims of this study were (1) to assess cardiorespira-
tory responses to the 6MWT in people with ILD; and
(2) to compare cardiorespiratory responses with those
obtained during CPET.
Methods
Patients with documented ILD of any etiology were re-
cruited from a tertiary hospital in Melbourne, Australia.
Diagnosis was made according to established criteria
[6,18]. Patients were eligible to participate if they were
ambulant and able to ride a stationary cycle ergometer.
Exclusion criteria were clinical instability, history of syn-
cope on exertion and presence of comorbidities that
precluded exercise testing (for example, orthopedic or
neurological disease). Patients were also excluded if
they had resting oxygen saturation (SpO2) <88% on
room air, as supplemental oxygen was not used during
the metabolic monitoring. Measurements of spirom-
etry and TLCO were obtained to quantify disease severity.
Right ventricular systolic pressure was estimated on trans-
thoracic echocardiogram. The research protocol was ap-
proved by the hospital and university Human Research
Ethics Committees and written informed consent was ob-
tained from each participant prior to testing (H2008/
03363, FHEC08-021).
Study design and procedures
Participants performed the 6MWT and CPET in random
order to offset the possible confounding effect of fatigue.
All tests were performed in the morning and partici-
pants were permitted to take their regular medications
prior to testing. Test order was concealed in a sealedopaque envelope until just prior to the first test. An
interval of at least 60 minutes was provided between
tests.
Cardiorespiratory responses to exercise
Cardiorespiratory response to the tests was measured
directly using a portable metabolic monitoring system
(MetaMax 3B, Cortex, Germany). This system weighs
approximately 570 grams and is designed to be worn on
the chest with a harness. A turbine digital transducer
measured inspired and expired airflow via a facemask,
while an electrochemical cell oxygen analyzer and an in-
frared carbon dioxide analyzer simultaneously measured
expired gases. Values of breath-by-breath oxygen uptake
(VO2), carbon dioxide production (VCO2) and minute
ventilation (VE) were averaged every 20 seconds. The
system was calibrated before each test according to the
manufacturer's specifications. Heart rate (HR) and rhythm
were monitored through a 3-lead electrocardiogram
(ECG). Data were recorded via telemetry, stored in an
on-board memory and then downloaded to a computer
for analysis.
Oxyhemoglobin saturation was monitored continu-
ously during the tests using a portable pulse oximeter
(Tuffsat, GE Healthcare, Finland). Baseline SpO2, nadir
SpO2 (the lowest SpO2 during the test) and end-test
SpO2 (the SpO2 at the point of test termination) were
recorded. The modified Borg score (0–10 scale) was
used to measure dyspnea and leg fatigue at baseline and
at the end of each test.
6-minute walk test
The 6MWT was performed according to standardised
criteria [19]. Participants were instructed to walk as far
as possible along a 30-meter corridor for six minutes,
with the aim of achieving their maximum possible walk-
ing distance in six minutes. Standardised instructions
were provided and standardised encouragement was
given each minute. Participants were permitted to stop
and rest if required but were encouraged to continue
walking as soon as they were able. To control for any
learning effect, two tests were performed, separated by
at least 30 minutes of rest. The best distance was re-
corded. The VO2peak during the 6MWT was defined
as the highest of the 20-second averaged oxygen con-
sumption measured between 2nd-6th minute.
Cardiopulmonary exercise test
A symptom limited incremental protocol was performed
on an electronically braked cycle ergometer (Corival V2,
Lode BV, Netherlands). Participants were instructed to
rest for two minutes and then cycle at between 50–
60 rpm. Initial workload was 10 Watts (W). Thereafter,
work rate was increased by 10 W increments each minute
Table 1 Baseline demographic characteristics of
participants
All IPF Non-IPF
Sample, n 47 27 20
Age, years 71 (11) 74 (8) 67 (15)
Gender - Male 34 (77) 21 (78) 13 (65)
FVC, % predicted 74 (18) 73 (20) 75 (18)
TLCO, % predicted 49 (14) 44 (11) 55 (17)*
RVSP, mmHg 35 (15) 39 (18) 28 (5)
VO2peak, ml.kg
-1.min-1 16 (4) 15 (4) 17 (4)
VO2peak, % predicted 68 (24) 64 (21) 74 (28)
6MWD, meters 429 (130) 414 (142) 448 (114)
Results are expressed as mean (SD) or n(%). ILD = interstitial lung disease,
IPF = interstitial pulmonary fibrosis, FVC = forced vital capacity, TLCO = diffusing
capacity for carbon monoxide, RVSP = right ventricular systolic pressure,
VO2peak = peak oxygen uptake, 6MWD = 6-minute walk distance. *p<0.05 vs
IPF subgroup.
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ited exhaustion. This protocol was selected to ensure that
the highest possible peak workload was achieved [20,21].
For the CPET, VO2peak was defined as the highest of the
20 second averaged oxygen consumption measured in the
last minute of the test.
Statistical analysis
We hypothesized that the VO2peak would be signifi-
cantly higher during CPET. The sample size requirement
for this study was calculated based on the results of our
pilot data where VO2peak was 0.12 L.min
−1 higher (SD
of 0.29 L.min−1) than the 6MWT [22]. According to this
calculation, a sample of 47 participants was necessary to
provide a statistical power of 80% with a two-sided 0.05
significance level.
Statistical analysis was performed using SPSS software
version 19.0 (Chicago, Illinois, USA). Metabolic response
to the CPET and 6MWT was compared using paired t
tests. One-way analysis of variance (repeated measures)
was used to analyze the VO2 profile throughout the
6MWT. Relationships between important CPET out-
comes (VO2peak and nadir SpO2) and 6MWT outcomes
(6MWD, 6MWT VO2peak and 6MWT nadir SpO2) were
examined using Pearson’s correlation coefficients (r) for
normally distributed data. A pre-specified subgroup ana-
lysis was performed for participants with IPF. All data are
expressed as mean (SD) unless otherwise stated. A p value
of <0.05 was considered statistically significant.
Results
Forty seven participants were included in the study. Twenty
seven (57%) had IPF. Other diagnoses included: asbestosis
(n = 8), connective tissue related ILD (n = 3), sarcoid-
osis (n = 4), non-specific interstitial pneumonia (n = 3)
and hypersensivity pneumonitis (n = 2). The baseline
characteristics of the participants are presented in
Table 1. Participants with IPF had similar characteris-
tics to those with other ILDs apart from a lower TLCO
% predicted.
Oxygen uptake increased progressively over the first
three minutes of the 6MWT and achieved a plateau over
the last three minutes (Figure 1). The same pattern of
progression was observed in the subgroup of participants
with IPF (0.77(0.23), 0.99(0.28) and 1.06(0.29) L.min−1
at 1, 2 and 3 minutes; p < 0.05 vs previous minute; 1.07
(0.29), 1.08(0.29) and 1.1(0.29) L.min−1 at 4, 5 and
6 minutes, p > 0.05 versus previous minute).
The 6MWT VO2peak was significantly lower than that
recorded during the CPET, averaging 94% of CPET
VO2peak (p = 0.006 for comparison between exercise
tests, Table 2). However there was wide variability be-
tween individuals, with 6MWT VO2peak ranging from
62% to 135% of VO2peak on CPET. Forty-five percent ofindividuals had a higher VO2peak during the 6MWT
compared to the CPET. Eight participants stopped to
rest during the 6MWT due to intolerable dyspnea, how-
ever the difference between tests persisted when these in-
dividuals were excluded from analysis (6MWT VO2peak
92% of CPET VO2peak, p < 0.001). The 6MWT was
ceased due to dyspnea in 32 participants (68%) and
due to leg fatigue in seven participants (15%), whilst
the CPET was ceased due to dyspnea in 25 participants
(53%) and due to leg fatigue in 11 participants (23%, p =
0.07 for comparison between tests).
The 6MWT VO2peak was a significantly higher per-
centage of CPET VO2peak in participants who had a
lower TLCO%predicted (r = −0.43, p = 0.003, Figure 2)
and greater desaturation during walking (r = −0.46, p =
0.01, Figure 3). There was no effect on the percentage of
VO2peak achieved during 6MWT related to 6MWD,
age, height, FVC, RVSP or percentage of peak HR
achieved during walking. Other cardiorespiratory vari-
ables (VCO2peak, VEpeak and HRpeak) and scores of
dyspnoea and fatigue were lower during the 6MWT in
comparison to the CPET (p < 0.01). However, 37 par-
ticipants (79%) desaturated more during the 6MWT
than in the CPET (mean difference between tests 2.8%,
p < 0.001). A similar pattern of differences in cardiore-
spiratory response was seen in the subgroup of partici-
pants with IPF, however the reduction in VO2peak on
6MWT was smaller and did not reach statistical sig-
nificance (Table 2). Eighty-nine percent of participants
with IPF desaturated more on the 6MWT than on the
CPET (mean difference 3.4%, p < 0.001).
Longer 6MWDs were associated with a greater VO2peak
during walking (r = 0.79, p < 0.001). Both the 6MWD and
6MWT VO2peak were strongly correlated with CPET
VO2peak (r = 0.71 for both; p < 0.001) and with other
CPET measures including peak work and VCO2peak
Figure 1 Oxygen uptake (VO2) profile during the six-minute walk test. Data are mean and standard deviation. * represents significant difference
compared to previous minute on 6MWT.
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6MWT VO2peak to other established measures of out-
come and prognosis, such as respiratory function vari-
ables, was weak to moderate. In contrast, the nadir
SpO2 on 6MWT had stronger relationships with prog-
nostic variables such as FVC and TLCO%predicted
and little relationship to other exercise responses in-
cluding VO2peak. A similar pattern of results was ob-
served in participants with IPF (Table 3).
Discussion
Our direct comparison of the cardiorespiratory responses
during the 6MWTand CPET in people with ILD provides
novel physiological data to explain the different perform-
ance characteristics of these important tests. This study
has shown that, on average, the 6MWT elicits a high butTable 2 Comparison of cardiorespiratory responses to CPET a
All (n =47) IP
CPET 6MWT p value CPET
VO2peak, L.min
−1 1.25 (0.37) 1.16 (0.27) 0.006 1.19 (0.25
VCO2peak, L.min
−1 1.38 (0.43) 1.05 (0.30) <0.001 1.36 (0.37
VEpeak, L.min−1 55.5(16.6) 42.8 (14.2) <0.001 56.8 (14.6
HRpeak, bpm 127 (20.1) 118 (14.8) 0.001 126.1 (19.1
NadirSpO2, % 89.3 (4.7) 86.5 (6.2) <0.001 88.7 (5.4)
Borg dyspnoea score 4.8 (1.6) 3.7 (1.3) <0.001 5.1 (1.8)
Borg fatigue score 4.1 (2.3) 3.0 (1.9) 0.001 3.9 (2.4)
Results are expressed as mean(SD). CPET = cardiopulmonary exercise test, 6MWT = s
dioxide production, VEpeak = peak minute ventilation, HRpeak = peak heart rate, Na
between tests.submaximal VO2 in people with ILD that reaches a plat-
eau after the third minute of the test. This supports the
conceptualization of the 6MWT as a submaximal, steady
state exercise test. However there is variability in re-
sponses that is related to disease stage. The 6MWT
imposes a greater cardiorespiratory load on those with
greater disease severity, where the peak VO2 can equal
or exceed the VO2peak seen during a CPET. Oxy-
haemoglobin desaturation was significantly greater during
the 6MWT than the CPET and this was unrelated to the
physiological load imposed by the test. These findings
may assist in explaining the superior performance of oxy-
haemoglobin desaturation compared to 6MWD as prog-
nostic indicator in people with ILD.
It has previously been suggested that the self-paced nature
of the 6MWT may contribute to the reduced predictivend 6MWT
F Subgroup (n = 27) Non-IPF Subgroup (n = 20)
6MWT p value CPET 6MWT p value
) 1.15 (0.23) 0.20 1.46 (0.46) 1.22 (0.33) 0.002
) 1.05 (0.25) <0.001 1.53 (0.52) 1.12 (0.34) <0.001
) 47.2 (17.1) <0.001 56.9 (20.6) 36.8 (12.1) <0.001
) 118.3 (16.3) 0.009 128.6 (21.9) 118.5 (13.0) 0.03
85.3 (6.2) <0.001 90.2 (3.9) 88.1 (6.1) 0.07
4.0 (1.6) 0.006 4.6 (1.3) 3.5 (1.1) <0.001
2.5 (1.3) 0.004 4.4 (2.4) 3.7 (2.5) 0.13
ix-minute walk test, VO2peak = peak oxygen uptake, VCO2peak = peak carbon
dirSpO2 = lowest oxyhaemoglobin saturation. p values are for comparison
Figure 2 Relationship between TLCO%predicted and % of peak VO2 achieved during 6MWT.
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ferences between 6MWT and CPET in VCO2peak and
VEpeak, indicating a much lower physiological load for the
6MWT. This is similar to previous findings in COPD
[23-26] and may reflect a smaller exercising muscle mass
and greater lactate production during the CPET. More im-
portantly, our results indicate that the 6MWT protocol fre-
quently allows people with mild disease to exercise at a
much lower percentage of their CPET VO2peak than those
with more advanced disease. Not surprisingly, we found that
a lower VO2peak was associated with lower 6MWD. This
variability in the load imposed by the 6MWT across the
range of disease severity may contribute to the inconsistencyFigure 3 Relationship between nadir SpO2 on 6MWT and % of peak Vof 6MWD as a marker of prognosis across study popula-
tions [8-10].
In contrast, the degree of desaturation during exercise
was unaffected by the VO2 elicited during the test. Al-
though there was desaturation during both exercise
tests, it was significantly greater during walking than
during cycling for the vast majority of participants
(Table 2). This is consistent with previous findings in
COPD [17], which showed increased alveolar ventilation
during cycling compared to treadmill walking, with a
concomitant increase in partial pressure of oxygen in ar-
terial blood (PaO2) which minimized the magnitude of
oxyhaemoglobin desaturation during cycling. The increaseO2 achieved during 6MWT.
Table 3 Relationship of 6-minute walk test outcomes to cardiopulmonary exercise test and demographics





















0.71** 0.71** 0.28 0.74** 0.79** 0.24 0.55* 0.77** 0.35
CPET VCO2peak,
L.min−1
0.77** 0.74** 0.19 0.77** 0.78** 0.14 0.69** 0.80** 0.35
CPET VEpeak,
L.min−1
0.36* 0.21 −0.03 0.31 0.24 −0.37 0.46* 0.71** 0.29
CPET Peak Work,
Watts
0.77** 0.38* 0.35* 0.86** 0.64** 0.15 0.73** 0.62** 0.48*
CPET NadirSpO2, % 0.21 0.13 0.76** 0.25 0.29 0.85** 0.05 0.03 0.61**
Age, years −0.42** −0.14 −0.23 −0.42* −0.41* 0.04 −0.47* −0.09 −0.35
Height, cm 0.09 −0.20 0.10 0.10 0.06 −0.15 0.15 0.51* 0.35
FVC%pred 0.22 −0.12 0.50** 0.13 0.04 0.49* 0.37 0.04 0.52*
TLCO%pred 0.34* 0.14 0.60** 0.28 0.35 0.64** 0.39 0.27 0.47*
RVSP, mmHg −0.46* −0.33 −0.48 −0.49 −0.43 −0.47 −0.16 0.37 0.73
Data are Pearson’s r. *p <0.05, **p < 0.01 for relationship between variables. CPET = cardiopulmonary exercise test, VO2peak = peak oxygen uptake, 6MWT = six-minute
walk test, 6MWD= six-minute walk distance, NadirSpO2 = lowest oxyhaemoglobin saturation, VO2 – oxygen uptake, VCO2 - carbon dioxide production, VE – ventilation,
FVC – forced vital capacity, TLCO – diffusing capacity for carbon monoxide, RVSP – right ventricular systolic pressure on trans-thoracic echocardiogram.
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prior to the anabolic threshold, which suggests that both
neurogenic feedback from exercising muscles andearlier
onset of anaerobic metabolism were contributors to better
maintained oxyhaemoglobin saturation [17]. Whilst previ-
ous studies have found a consistent relationship be-
tween desaturation on 6MWT and poor prognosis,
[2,15,16] the relationship between desaturation on
CPET and prognosis is less consistent [2,3,27]. This
may be because the lesser degree of desaturation on
the CPET was not sufficient to discriminate those at
risk of a poor outcome. Our data suggest that a greater
degree of desaturation occurs during a 6MWT regard-
less of the physiological load imposed by the test, and
this may be the most robust outcome of the 6MWT.
To date this is the largest study to compare the
physiological responses to the CPET and 6MWT in indi-
viduals with any form of chronic lung disease. This may
explain differences in our findings compared to others.
One previous study included 13 individuals with ILD (12
IPF) and did not find a difference in VO2peak on
6MWT compared to CPET [14]. However, the small
numbers of participants may have reduced the ability to
detect small differences and did not allow the authors to
assess effects attributable to disease severity. Their study
also excluded people with pulmonary hypertension and
thus the findings cannot be generalized to patients with
more severe disease, where pulmonary hypertension is
relatively common [28]. Studies which have examined
the physiological load associated with the 6MWT in
COPD have also found no difference in VO2peakbetween 6MWT and CPET [23-26]. This may represent
a real difference in response across disease groups, or
may reflect the smaller subject numbers in those studies
(n = 12 to 26). It should be noted that we did not find a
difference in mean VO2peak between tests when the
subgroup of participants with IPF was examined separ-
ately (n = 27), however this study was not powered to as-
sess differences in this subgroup and results should be
interpreted with caution.
Other limitations to this study include conducting the
exercise tests on the same day, such that fatigue may
have impacted on results; however the order of testing
was randomized to account for any potential order ef-
fects. Our exclusion criteria did not allow participation
by patients with resting SpO2 of less than 88%, as sup-
plemental oxygen was not applied during metabolic
monitoring; our results therefore may not apply to pa-
tients with ILD and severe resting hypoxemia. Finally, a
number of participants (n = 8) stopped during the 6MWT
due to intolerable dyspnea, which occurs commonly in
this group. This may have affected the physiological data
collected and a steady state may not have been achieved.
However, the difference between tests persists when these
individuals are excluded from analysis.
Conclusions
This study shows that the 6MWT elicits high but submaxi-
mal cardiorespiratory responses in people with ILD. There
is wide variability across the range of disease severity, such
that the 6MWT may elicit a higher VO2peak for those with
more severe disease. Exertional desaturation is greater on
Holland et al. BMC Pulmonary Medicine 2014, 14:136 Page 7 of 8
http://www.biomedcentral.com/1471-2466/14/1366MWT than CPET and this is unaffected by the physio-
logical load. These data suggest that desaturation during a
6MWT may provide unique and consistent information
across the range of disease severity in ILD.
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